GLOBAL NPHP5 RETINAL DEGENERATION TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type (Gene Therapy, Cell Therapy, Drug Therapy, Others), By Indication (Retinitis Pigmentosa, Leber Congenital Amaurosis, Usher Syndrome, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global NPHP5 Retinal Degeneration Treatment Market – Key Developments

On October 16, 2023, The Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, announced an investment in NVasc, an early-stage company focused on treating age-related macular degeneration (AMD).
On April 26, 2023, RetinAI Medical, a medical technology company, announced a partnership with Boehringer Ingelheim, a global pharmaceutical company, to improve retinal disease treatment. Under the terms of the partnership, RetinAI will test its AI tools by analyzing Boehringer Ingelheim’s imaging datasets from clinical studies and real-world evidence. The aim is to identify novel biomarkers and predictors of disease progression that could accelerate the development of urgently needed treatments.